UPDATE: Piper Jaffray Starts Moderna (MRNA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Needham & Company Starts Moderna (MRNA) at Buy
January 2, 2019 6:45 AM ESTNeedham & Company analyst Alan Carr initiates coverage on Moderna (NASDAQ: MRNA) with a Buy rating and a price target of $28.00.
Carr commented, "Moderna is leveraging an mRNA drug/ drug delivery platform to generate an extensive pipeline across oncology, infectious diseases, cardiology, and rare... More
BofA/Merrill Lynch Starts Moderna (MRNA) at Buy
January 2, 2019 6:14 AM ESTBofA/Merrill Lynch analyst Ying Huang initiates coverage on Moderna (NASDAQ: MRNA) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $15.27 yesterday.
... MoreOppenheimer Starts Moderna (MRNA) at Outperform
January 2, 2019 6:10 AM ESTOppenheimer analyst Leah Rush Cann initiates coverage on Moderna (NASDAQ: MRNA) with a Outperform rating and a price target of $27.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $15.27 yesterday.
... MoreGoldman Sachs Starts Moderna (MRNA) at Buy
January 2, 2019 4:51 AM ESTGoldman Sachs analyst Salveen Richter initiates coverage on Moderna (NASDAQ: MRNA) with a Buy rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $15.27 yesterday.
... MoreMorgan Stanley Starts Moderna (MRNA) at Overweight
January 2, 2019 3:35 AM ESTMorgan Stanley analyst Matthew Harrison initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $29.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $15.27 yesterday.
... MoreJPMorgan Starts Moderna (MRNA) at Overweight
January 2, 2019 3:28 AM ESTJPMorgan analyst Cory Kasimov initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $15.27 yesterday.
... MoreUPDATE: Barclays Starts Moderna (MRNA) at Overweight
January 2, 2019 3:27 AM EST(Updated - January 2, 2019 3:29 AM EST)
(updated to correct company name)
Barclays analyst Geoff Meacham initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $20.00.
For an analyst ratings summary and ratings history on... More
